Importance Proposed biosimilar natalizumab (biosim-NTZ) PB006 is the first biosimilar
monoclonal antibody therapy developed for multiple sclerosis (MS) treatment. Objective To …

Background: Relatively little is known about the use of disease-modifying drugs (DMDs) for
multiple sclerosis (MS) in the population-based universal healthcare setting. This study …

Background: A diagnosis of multiple sclerosis (MS) can be categorized based on its disease
course into the following phenotypes: relapsing-remitting MS (RRMS), primary progressive …

Objective To evaluate the 5-year real-world benefit–risk profile of fingolimod in patients with
relapsing–remitting MS (RRMS) in Germany. Methods Post-Authorization Non-interventional …

Background: For the case of multiple sclerosis, research on gender differences from a health
economics perspective has not received much attention. However, cost-of-illness analyses …

Background Multiple sclerosis (MS) is a progressively debilitating neurologic disease that
poses significant costs to the healthcare system and workforce. Objective To evaluate the …

Background: Persons with multiple sclerosis (PwMS) typically require complex
multidisciplinary care, which is rarely formally assessed. Objectives: We applied …

Background Previous investigations of multiple sclerosis (MS)-related healthcare have
focused on utilisation of specific individual health services (eg hospital care, office-based …

Abstract Background Most Multiple Sclerosis (MS) clinical trials fail to assess the long-term
effects of disease-modifying therapies (DMT) or disability. Methods COLuMbus was a single …

Background The burden of disease for persons with multiple sclerosis (MS) and society is
changing due to new treatments. Knowledge about the total need for care is necessary in …